Core Viewpoint - The stock of Hongbo Pharmaceutical (301230) has experienced significant trading volatility, with a cumulative price deviation exceeding 30% over two consecutive trading days and over 100% over five trading days [1] Group 1: Stock Performance - The company's stock price has shown a cumulative deviation of over 30% in closing prices for two consecutive trading days [1] - Over a span of five trading days, the cumulative deviation in closing prices has exceeded 100% [1] Group 2: Company Operations - The company reports that its operations are normal and there have been no significant changes [1] - The direct revenue from the DiOrion platform drug development services constitutes a small portion of the company's overall revenue and does not significantly impact the overall business performance [1]
泓博医药：公司DiOrion平台药物研发服务的直接收入占比较小